Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Tirzepatide mimics and amplifies the effects of these hormones. By mimicking the GLP-1 and GIP hormones, tirzepatide makes people feel fuller with smaller meals. This can reduce the overall food ...

The UK Government has signed a collaboration agreement with Lilly, the pharmaceutical giant behind weight loss medication ...

The Government is considering using drugs to help get obese people back to work - but they can lead to serious health ...

Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

Tirzepatide for diabetes vs long-acting insulins demonstrated superior glycemic control and weight loss compared among adults with type 2 diabetes.

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...